Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines

Summary Treatment of B-cell non-Hodgkin lymphomas has undergone substantial developments in the past 10 years. The introduction of rituximab has greatly improved survival outcomes in patients. Clinical practice guidelines based on current evidence have been developed to provide recommendations for s...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2013-11, Vol.14 (12), p.e548-e561
Main Authors: Tan, Daryl, Dr, Tan, Soo Yong, MD, Lim, Soon Thye, MD, Kim, Seok Jin, MD, Kim, Won-Seog, Prof, Advani, Ranjana, Prof, Kwong, Yok-Lam, Prof
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - standards
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Asia - epidemiology
Delivery of Health Care - standards
Epstein-Barr virus
Health Resources - economics
Health Resources - standards
Health Services Accessibility - standards
Healthcare Disparities - standards
Hematology, Oncology and Palliative Medicine
Humans
Low income groups
Lymphoma
Lymphoma, B-Cell - diagnosis
Lymphoma, B-Cell - mortality
Lymphoma, B-Cell - therapy
Medical Oncology - economics
Medical Oncology - standards
Medical prognosis
Predictive Value of Tests
Radiotherapy, Adjuvant - standards
Stem Cell Transplantation - standards
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Treatment of B-cell non-Hodgkin lymphomas has undergone substantial developments in the past 10 years. The introduction of rituximab has greatly improved survival outcomes in patients. Clinical practice guidelines based on current evidence have been developed to provide recommendations for standard treatment approaches. However, guidelines do not take into account resource limitations in resource-poor countries. The huge disparities in economy, health-care infrastructure, and access to novel drugs between Asian countries can hinder the delivery of optimum care to patients with lymphoma in Asia. We outline guidelines appropriate to different levels of health-care resources and expertise, aiming to provide advice on diagnosis and treatment, unify interpretation of results, and allow the design of future studies in Asia. In this resource-adapted consensus, we summarise recommendations for diagnosis, staging, risk stratification, and treatment of common B-cell non-Hodgkin lymphomas in Asia.
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(13)70450-9